MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
long-term debt
$400,000K
Net proceeds from
common stock issued...
$19,479K
(715.02%↑ Y/Y)
Common stock issued to
directors in lieu of cash...
$33K
(450.00%↑ Y/Y)
Net cash provided by
financing activities
$412,552K
(77887.15%↑ Y/Y)
Canceled cashflow
$6,960K
Net increase in
cash, and cash...
$82,041K
(14602.69%↑ Y/Y)
Canceled cashflow
$330,511K
Payment of debt issuance
costs on term loan
$4,952K
Withholding taxes paid on
stock-based awards
$1,187K
(-12.14%↓ Y/Y)
Principal payments on
royalty financing...
$476K
Principal payments on
finance lease...
$345K
(-33.14%↓ Y/Y)
Sales and maturities
of investments
$221,235K
(191.10%↑ Y/Y)
Acquired in-process
research and development
$697,761K
Stock-based compensation
expense
$16,027K
(-25.00%↓ Y/Y)
Non-cash interest
expense on royalty...
$13,294K
Decrease (increase) in
prepaid expenses and...
-$3,532K
(-2775.76%↓ Y/Y)
Mark-to-market adjustment on
share-based liability
-$2,807K
Amortization of assembled
workforce
$600K
Depreciation
$461K
Amortization of premium
(discount) on investments,...
$251K
(118.15%↑ Y/Y)
Amortization of debt issuance
costs on term loans
$149K
Inventory obsolescence
$74K
(-64.59%↓ Y/Y)
Net cash (used in)
provided by investing...
-$268,648K
(-1091.50%↓ Y/Y)
Net cash used in
operating activities
-$61,791K
(-124.56%↓ Y/Y)
Effect of exchange
rates on cash, cash...
-$72K
(-115.96%↓ Y/Y)
Canceled cashflow
$221,235K
Canceled cashflow
$734,956K
Total revenues
$156,413K
(7.48%↑ Y/Y)
Interest income
$2,256K
(-25.40%↓ Y/Y)
Acquisition of astria
therapeutics, inc., net of cash...
$489,480K
Net (loss) income
-$721,812K
(-2255762.50%↓ Y/Y)
Acquisitions of property and
equipment
$403K
(181.82%↑ Y/Y)
Canceled cashflow
$158,669K
Decrease in accounts
payable and accrued...
-$60,395K
(-28.11%↓ Y/Y)
Decrease in royalty
financing obligations
-$8,470K
Increase in inventory
$4,847K
(457.13%↑ Y/Y)
Decrease in deferred
revenue
-$749K
Increase in receivables
$474K
(-96.61%↓ Y/Y)
Acquired in-process
research and development
$697,761K
Sales and marketing
(excluding stock-based...
$42,953K
(-47.92%↓ Y/Y)
General and
administrative (excluding...
$42,393K
Research and development
(excluding stock-based...
$27,091K
Interest expense
$19,779K
(-15.81%↓ Y/Y)
Stock-based compensation
$16,027K
Research and development
(excluding stock-based...
$9,741K
Research and development
(excluding stock-based...
$7,419K
Cost of product sales
$5,377K
(17.71%↑ Y/Y)
Research and development
(excluding stock-based...
$3,970K
Research and development
(excluding stock-based...
$1,907K
(-73.91%↓ Y/Y)
Research and development
(excluding stock-based...
$1,796K
Other expense, net
-$1,462K
Income tax expense
$1,004K
(38.29%↑ Y/Y)
Research and development
(excluding stock-based...
$893K
Research and development
(excluding stock-based...
$683K
Foreign currency losses
(gains), net
-$225K
Back
Back
Cash Flow
BIOCRYST PHARMACEUTICALS INC (BCRX)
BIOCRYST PHARMACEUTICALS INC (BCRX)
source: myfinsight.com